Teoxane SA Monday revealed a proposal to acquire Revance Therapeutics, Inc. (RVNC) for $3.60 per share in cash. The Geneva, Switzerland-based medical aesthetics sector company said it currently owns 6.2 percent stake in Revance.
RVNC is currently up 16.02 percent at $3.58 on a volume of 4,461,212.
The offer provides a 16 percent premium over the $3.10 per share price in Revance's amended and restated merger agreement with Crown Laboratories, Inc., as on December 9, 2024.
Teoxane said it is already in discussions with financing sources to secure committed financing.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.